Laprem (Lapatinib)

Lapatinib blocks the intracellular kinase activity of both EGFR (ErbB1) and HER2 (ErbB2). By preventing ATP binding, it stops downstream signaling through pathways such as MAPK and PI3K/AKT, leading to reduced cancer cell proliferation, survival, and angiogenesis in tumors that overexpress these receptors.

The specific dose of Laprem is determined by the prescribing physician based on the patient’s clinical condition, prior therapies, and organ function. Dosage adjustments may be required for hepatic impairment or drug‑drug interactions, and the prescriber will provide detailed instructions.

Safety of lapatinib in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception.

To request Laprem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to lapatinib is trastuzumab, a monoclonal antibody that also targets HER2 but binds extracellularly. Lapatinib, as a small‑molecule tyrosine kinase inhibitor, can be taken orally and may be effective in patients who have progressed on trastuzumab or have brain metastases, whereas trastuzumab requires intravenous infusion.

Laprem should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in areas with high humidity or direct sunlight.

Laprem is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water and follow any specific timing instructions related to other medications to avoid absorption issues.

The most serious adverse events include hepatotoxicity (elevated liver enzymes or liver failure), cardiac dysfunction such as reduced left‑ventricular ejection fraction, severe skin reactions like Stevens‑Johnson syndrome, interstitial lung disease, and thromboembolic events. Patients should report any signs of liver injury, shortness of breath, or unusual skin changes promptly.

Laprem is contraindicated in patients with known hypersensitivity to lapatinib or any of its excipients, in those with severe hepatic impairment, and in individuals with a history of serious cardiac dysfunction unless closely monitored. Caution is also advised for patients taking strong CYP3A4 modulators or those with uncontrolled QT prolongation.